A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging

David I. Rosenthal, Pamela Nurenberg, Carlos R. Becerra, Eugene P. Frenkel, David P. Carbone, Bert L. Lum, Richard Miller, Julie Engel, Stuart Young, Dale Miles, Markus F. Renschler

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Gadolinium Texaphyrin (Gd-Tex) is a radiation sensitizer with a novel mechanism of action that sensitizes both oxic and hypoxic cells, localizes selectively in tumors, and is detectable by magnetic resonance imaging (MRI). This Phase I single-dose trial of Gd-Tex administered concurrently with radiation therapy was carried out to determine the maximally tolerated dose (MTD), dose-limiting toxicities, pharmacokinetics, and biolocalization of Gd- Tex as determined by MRI. Adults with incurable cancers of any histology requiring radiation therapy were eligible. A single i.v. dose of Gd-Tex was followed at least 2 h later by radiation therapy. The Gd-Tex dose was escalated in cohorts of 3 to 5 patients. Thirty-eight patients (median age, 58 years; range, 35-77 years) with incurable cancers of the lung (26), cervix (3), or other solid tumors (9) received a total of 41 single administrations of Gd-Tex. The Gd-Tex dose was escalated from 0.6 to 29.6 mg/kg. Irradiated sites included the thorax, brain, pelvis, bone, soft tissue, and sites of nodal metastases. The MTD was 22.3 mg/kg, determined by reversible acute tubular necrosis as the dose-limiting toxicities. Gd-Tex selectively accumulated in primary and metastatic tumors as demonstrated by MRI. No increase in radiation toxicity to normal tissues was seen. The median half- life of Gd-Tex after single-dose administration is 7.4 h. This study demonstrates that Gd-Tex is well tolerated in doses below the MTD, and that there is selective biolocalization in tumors. The maximum recommended dose for single administrations is 16.7 mg/kg.

Original languageEnglish (US)
Pages (from-to)739-745
Number of pages7
JournalClinical Cancer Research
Volume5
Issue number4
StatePublished - Apr 1999

Fingerprint

Radiation-Sensitizing Agents
Magnetic Resonance Imaging
Neoplasms
Maximum Tolerated Dose
Radiotherapy
motexafin gadolinium
Pelvis
Cervix Uteri
Half-Life
Lung Neoplasms
Histology
Necrosis
Thorax
Pharmacokinetics
Radiation
Neoplasm Metastasis
Bone and Bones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rosenthal, D. I., Nurenberg, P., Becerra, C. R., Frenkel, E. P., Carbone, D. P., Lum, B. L., ... Renschler, M. F. (1999). A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clinical Cancer Research, 5(4), 739-745.

A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. / Rosenthal, David I.; Nurenberg, Pamela; Becerra, Carlos R.; Frenkel, Eugene P.; Carbone, David P.; Lum, Bert L.; Miller, Richard; Engel, Julie; Young, Stuart; Miles, Dale; Renschler, Markus F.

In: Clinical Cancer Research, Vol. 5, No. 4, 04.1999, p. 739-745.

Research output: Contribution to journalArticle

Rosenthal, DI, Nurenberg, P, Becerra, CR, Frenkel, EP, Carbone, DP, Lum, BL, Miller, R, Engel, J, Young, S, Miles, D & Renschler, MF 1999, 'A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging', Clinical Cancer Research, vol. 5, no. 4, pp. 739-745.
Rosenthal, David I. ; Nurenberg, Pamela ; Becerra, Carlos R. ; Frenkel, Eugene P. ; Carbone, David P. ; Lum, Bert L. ; Miller, Richard ; Engel, Julie ; Young, Stuart ; Miles, Dale ; Renschler, Markus F. / A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 4. pp. 739-745.
@article{e579cd921bf24b5b83eedde494e52c48,
title = "A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging",
abstract = "Gadolinium Texaphyrin (Gd-Tex) is a radiation sensitizer with a novel mechanism of action that sensitizes both oxic and hypoxic cells, localizes selectively in tumors, and is detectable by magnetic resonance imaging (MRI). This Phase I single-dose trial of Gd-Tex administered concurrently with radiation therapy was carried out to determine the maximally tolerated dose (MTD), dose-limiting toxicities, pharmacokinetics, and biolocalization of Gd- Tex as determined by MRI. Adults with incurable cancers of any histology requiring radiation therapy were eligible. A single i.v. dose of Gd-Tex was followed at least 2 h later by radiation therapy. The Gd-Tex dose was escalated in cohorts of 3 to 5 patients. Thirty-eight patients (median age, 58 years; range, 35-77 years) with incurable cancers of the lung (26), cervix (3), or other solid tumors (9) received a total of 41 single administrations of Gd-Tex. The Gd-Tex dose was escalated from 0.6 to 29.6 mg/kg. Irradiated sites included the thorax, brain, pelvis, bone, soft tissue, and sites of nodal metastases. The MTD was 22.3 mg/kg, determined by reversible acute tubular necrosis as the dose-limiting toxicities. Gd-Tex selectively accumulated in primary and metastatic tumors as demonstrated by MRI. No increase in radiation toxicity to normal tissues was seen. The median half- life of Gd-Tex after single-dose administration is 7.4 h. This study demonstrates that Gd-Tex is well tolerated in doses below the MTD, and that there is selective biolocalization in tumors. The maximum recommended dose for single administrations is 16.7 mg/kg.",
author = "Rosenthal, {David I.} and Pamela Nurenberg and Becerra, {Carlos R.} and Frenkel, {Eugene P.} and Carbone, {David P.} and Lum, {Bert L.} and Richard Miller and Julie Engel and Stuart Young and Dale Miles and Renschler, {Markus F.}",
year = "1999",
month = "4",
language = "English (US)",
volume = "5",
pages = "739--745",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging

AU - Rosenthal, David I.

AU - Nurenberg, Pamela

AU - Becerra, Carlos R.

AU - Frenkel, Eugene P.

AU - Carbone, David P.

AU - Lum, Bert L.

AU - Miller, Richard

AU - Engel, Julie

AU - Young, Stuart

AU - Miles, Dale

AU - Renschler, Markus F.

PY - 1999/4

Y1 - 1999/4

N2 - Gadolinium Texaphyrin (Gd-Tex) is a radiation sensitizer with a novel mechanism of action that sensitizes both oxic and hypoxic cells, localizes selectively in tumors, and is detectable by magnetic resonance imaging (MRI). This Phase I single-dose trial of Gd-Tex administered concurrently with radiation therapy was carried out to determine the maximally tolerated dose (MTD), dose-limiting toxicities, pharmacokinetics, and biolocalization of Gd- Tex as determined by MRI. Adults with incurable cancers of any histology requiring radiation therapy were eligible. A single i.v. dose of Gd-Tex was followed at least 2 h later by radiation therapy. The Gd-Tex dose was escalated in cohorts of 3 to 5 patients. Thirty-eight patients (median age, 58 years; range, 35-77 years) with incurable cancers of the lung (26), cervix (3), or other solid tumors (9) received a total of 41 single administrations of Gd-Tex. The Gd-Tex dose was escalated from 0.6 to 29.6 mg/kg. Irradiated sites included the thorax, brain, pelvis, bone, soft tissue, and sites of nodal metastases. The MTD was 22.3 mg/kg, determined by reversible acute tubular necrosis as the dose-limiting toxicities. Gd-Tex selectively accumulated in primary and metastatic tumors as demonstrated by MRI. No increase in radiation toxicity to normal tissues was seen. The median half- life of Gd-Tex after single-dose administration is 7.4 h. This study demonstrates that Gd-Tex is well tolerated in doses below the MTD, and that there is selective biolocalization in tumors. The maximum recommended dose for single administrations is 16.7 mg/kg.

AB - Gadolinium Texaphyrin (Gd-Tex) is a radiation sensitizer with a novel mechanism of action that sensitizes both oxic and hypoxic cells, localizes selectively in tumors, and is detectable by magnetic resonance imaging (MRI). This Phase I single-dose trial of Gd-Tex administered concurrently with radiation therapy was carried out to determine the maximally tolerated dose (MTD), dose-limiting toxicities, pharmacokinetics, and biolocalization of Gd- Tex as determined by MRI. Adults with incurable cancers of any histology requiring radiation therapy were eligible. A single i.v. dose of Gd-Tex was followed at least 2 h later by radiation therapy. The Gd-Tex dose was escalated in cohorts of 3 to 5 patients. Thirty-eight patients (median age, 58 years; range, 35-77 years) with incurable cancers of the lung (26), cervix (3), or other solid tumors (9) received a total of 41 single administrations of Gd-Tex. The Gd-Tex dose was escalated from 0.6 to 29.6 mg/kg. Irradiated sites included the thorax, brain, pelvis, bone, soft tissue, and sites of nodal metastases. The MTD was 22.3 mg/kg, determined by reversible acute tubular necrosis as the dose-limiting toxicities. Gd-Tex selectively accumulated in primary and metastatic tumors as demonstrated by MRI. No increase in radiation toxicity to normal tissues was seen. The median half- life of Gd-Tex after single-dose administration is 7.4 h. This study demonstrates that Gd-Tex is well tolerated in doses below the MTD, and that there is selective biolocalization in tumors. The maximum recommended dose for single administrations is 16.7 mg/kg.

UR - http://www.scopus.com/inward/record.url?scp=0032907689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032907689&partnerID=8YFLogxK

M3 - Article

C2 - 10213207

AN - SCOPUS:0032907689

VL - 5

SP - 739

EP - 745

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -